A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 166 participants.

Also called NCT01477853

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01477853
  • EudraCT 2011-003600-20
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01477853. Randomized; double masking; primary purpose treatment. Start 2011-10-24 (actual); primary completion 2012-12-04 (actual). Results posted on 2016-10-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Atorvastatin
Intervention (Other)
Placebo to sitagliptin
Intervention (Other)
Placebo to atorvastatin
Intervention (Drug)
Metformin (open-label)
Intervention (Drug)
Glimepiride (open-label)
Intervention (Drug)
Glimepiride (double-blind)
Intervention (Drug)
Placebo to glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01477853
Content hash
c051278cca7f50b2686c383cfdb03500bcc0515348c8b53bd1052d0d3383420c